{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-152493","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.841141+00:00","generated_at":"2026-06-01T06:52:20.017914+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study","bullets":["92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.","One Cohort 2 patient alive and progression-free at 34.9+ months; IDH-mutant glioma case.","No CRS, ICANS, or dose-limiting toxicities; common AEs were Grade 1-2 related to TMZ.","Phase 2 INB-400 now dosing newly diagnosed GBM patients with up to six infusions.","Radiographic improvements included resolution of midline shift and 36% lesion decrease in one patient."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-152493","json":"https://secwatch.observer/filing/0001193125-24-152493.json","markdown":"https://secwatch.observer/filing/0001193125-24-152493.md","text":"https://secwatch.observer/filing/0001193125-24-152493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/0001193125-24-152493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/d777605d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:52:20.017914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}